Skip to main content

Table 2 Summary of QTc prolongations (safety population)

From: Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

 

Treatment group, 90 mg (n = 8)

Treatment group, 135 mg (n = 5)

Total N = 13

Maximum value, n

  ≤ 450 msec

2

3

5

  > 450 to ≤480 msec

4

1

5

  > 480 to ≤500 msec

1

0

1

  > 500 msec

1

1

2

Maximum change from baseline, n

  ≤ 30 msec

2

0

2

  > 30 to ≤60 msec

2

2

4

  > 60 msec

4

3

7

  1. QTc corrected QT interval